Search

Search Constraints

You searched for: Author/Creator Reinacher-Schick, Anke

Search Results

3. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study. (March 2014)

4. Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis. Issue 4 (9th October 2021)

5. Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. (March 2023)

6. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. (September 2018)

7. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Issue 13 (October 2015)

8. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Issue 34 (1st December 2022)

9. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). Issue 1 (1st January 2022)

10. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. (29th November 2020)